ANI Pharmaceuticals Reports First Quarter 2020 Results and Appoints Interim CEO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
ANI Pharma (ANIP) Tops Q1 EPS by 15c; Suspends FY20 Guidance
May 7, 2020 8:35 AM EDTANI Pharma (NASDAQ: ANIP) reported Q1 EPS of $1.04, $0.15 better than the analyst estimate of $0.89. Revenue for the quarter came in at $49.8 million versus the consensus estimate of $50.23 million.
For the first quarter 2020, ANI reports:
Net revenues of $49.8 million versus $52.9 million in 2019GAAP net loss of $7.0 million and diluted GAAP loss per share of $0.59Adjusted non-GAAP EBITDA of $17.6 millionAdjusted non-GAAP diluted earnings per share of $1.04Arthur S. Przybyl, President and CEO,... More
